NewAmsterdam Pharma (NAMS) Current Leases (2021 - 2026)

NewAmsterdam Pharma has disclosed Current Leases across 6 years of filings, most recently posting $23000.0 for Q1 2026.

• Current Leases for Q1 2026 came in at $23000.0, down 90.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $23000.0 (down 90.87% YoY), and the FY2025 annual result was $136000.0, down 44.72% from the prior year.
• Current Leases came in at $23000.0 for Q1 2026 at NewAmsterdam Pharma, down from $136000.0 in the prior quarter.
• In the past five years, Current Leases ranged from a high of $252000.0 in Q1 2025 to a low of $23000.0 in Q1 2026.
• The 5-year median for Current Leases is $181000.0 (2025), against an average of $154841.4.
• Across the five-year window, Current Leases jumped 486.05% in 2025 and sank 90.87% in 2026, its largest moves.
• NewAmsterdam Pharma's Current Leases stood at $63255.3 in 2022, then dropped by 5.15% to $60000.0 in 2023, then jumped by 310.0% to $246000.0 in 2024, then sank by 44.72% to $136000.0 in 2025, then sank by 83.09% to $23000.0 in 2026.
• The last three Current Leases figures came in at $23000.0 (Q1 2026), $136000.0 (Q4 2025), and $181000.0 (Q3 2025), per Business Quant data.